Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 176

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection

Open access
Sulkowski, Mark S., Vargas, Hugo E., Di Bisceglie, Adrian M., Kuo, Alexander, Reddy, K. Rajender, Lim, Joseph K., Morelli, Giuseppe, Darling, Jama M., Feld, Jordan J., Brown, Robert S., Frazier, Lynn M., Stewart, Thomas G., Fried, Michael W., Nelson, David R., Jacobson, Ira M., Afdhal, N., Alam, I., Ben-Ari, Z., Bredfeldt, J., Brown, R.S., Chung, R.T., Darling, J., Harlan, W., Di Bisceglie, A.M., Dickson, R.C., Elbeshbeshy, H.A., Everson, G., Feld, J., Fenkel, J.M., Fried, M.W., Galati, J., Gordon, S.C., Hassan, M., Hawkins, T.N., Hinestrosa, F., Jacobson, I.M., Kerr, C.A., Kuo, A., Kwo, P.Y., Levitsky, J., Lim, J., Lok, A.S., Mailliard, M., Manns, M.P., Morelli, G., Muir, A.J., Nelson, D., O’Leary, J.G., Pearlman, B.L., Pockros, P., Ramani, A., Reau, N., Reddy, K.R., Schiff, E.R., Sherman, K.E., Shiffman, M.L., Smith, C., Spivey, J.R., Sterling, R.K., Sulkowski, M.S., Szabo, G., Terrault, N.A., Trautwein, C., Vargas, H.E., Watts, K., Williams, A., Zeuzem, S. · 2016 · Gastroenterology

Abstract

Background & Aims The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America. Methods We collected demographic, clinical, and virologic data, as well as reports of adverse outcomes, from sequential participants in HCV-TARGET—a prospective, observational cohort study of patients undergoing HCV treatment in routine clinical care settings. From January through October 2014, 836 patients with HCV genotype 1 infection began 12 weeks of treatment with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these patients received ribavirin. Most patients were male (61%), Caucasian (76%), or black (13%); 59% had cirrhosis. Most had failed prior treatment with peginterferon and ribavirin without (46%) or with telaprevir or boceprevir (12%). The primary outcome was sustained virologic response (SVR), defined as level of HCV RNA below quantification at least 64 days after the end of treatment (beginning of week 12 after treatment—a 2 week window). Logistic regression models with inverse probability weights were constructed to adjust for baseline covariates and potential selection bias. Results The overall rate of SVR rate was 84% (675/802 patients, 95% CI: 81–87%). Model-adjusted estimates indicate patients with cirrhosis, prior decompensation, and previous protease inhibitor treatments were less likely to achieve an SVR. The addition of ribavirin had no detectable effects on SVR. The most common adverse events were fatigue, headache, nausea, rash, and insomnia. Serious adverse events and treatment discontinuation occurred in only 5% and 3% of participants, respectively. Conclusions In a large, prospective observational cohort study, a 12 week regimen of simeprevir plus sofosbuvir was associated with high rates of SVR and infrequent treatment discontinuation. ClinicalTrials.gov: NCT01474811

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2015.10.013

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 176

Metadata

Authors
Sulkowski, M. S., Vargas, H. E., Di Bisceglie, A. M., Kuo, A., Reddy, K. R., Lim, J. K., Morelli, G., Darling, J. M., Feld, J. J., Brown, R. S., Frazier, L. M., Stewart, T. G., Fried, M. W., Nelson, D. R., Jacobson, I. M., Afdhal, N., Alam, I., Ben-Ari, Z., Bredfeldt, J., Brown, R. S., Chung, R. T., Darling, J., Harlan, W., Di Bisceglie, A. M., Dickson, R. C., Elbeshbeshy, H. A., Everson, G., Feld, J., Fenkel, J. M., Fried, M. W., Galati, J., Gordon, S. C., Hassan, M., Hawkins, T. N., Hinestrosa, F., Jacobson, I. M., Kerr, C. A., Kuo, A., Kwo, P. Y., Levitsky, J., Lim, J., Lok, A. S., Mailliard, M., Manns, M. P., Morelli, G., Muir, A. J., Nelson, D., O’Leary, J. G., Pearlman, B. L., Pockros, P., Ramani, A., Reau, N., Reddy, K. R., Schiff, E. R., Sherman, K. E., Shiffman, M. L., Smith, C., Spivey, J. R., Sterling, R. K., Sulkowski, M. S., Szabo, G., Terrault, N. A., Trautwein, C., Vargas, H. E., Watts, K., Williams, A., & Zeuzem, S.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2016-02
Volume
150
Issue
2
Pages
419-429
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2138619940
Cited by
176
References
2
FWCI
21.83
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. https://app.cochat.ai/papers/10.1053/j.gastro.2015.10.013
The paper
Sulkowski, M. S., Vargas, H. E., Di Bisceglie, A. M., Kuo, A., Reddy, K. R., Lim, J. K., Morelli, G., Darling, J. M., Feld, J. J., Brown, R. S., Frazier, L. M., Stewart, T. G., Fried, M. W., Nelson, D. R., Jacobson, I. M., Afdhal, N., Alam, I., Ben-Ari, Z., Bredfeldt, J., . . . Zeuzem, S. (2016). Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. https://doi.org/10.1053/j.gastro.2015.10.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.